Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02438904 · ClinicalTrials.gov registry record · NA
Compassionate Access of the Miltenyi Device for CD34+ Cell Selection
A NA study of Blood And Marrow Transplantation, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT02438904: Recruiting NA study of Blood And Marrow Transplantation, sponsored by M.D. Anderson Cancer Center.
NCT02438904 is a NA study of Blood And Marrow Transplantation that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 200 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02438904, a NA study of Blood And Marrow Transplantation, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Objectives: Primary Objective To provide compassionate access to the Miltenyi device for CD34+ cell infusions to patients who experience poor graft function after stem cell transplantation (SCT).
Primary Outcome
Blood drawn for signs of graft versus host disease (GVHD).
Conditions Studied
Interventions
- BIOLOGICAL CD34 Positive Stem Cell Infusion
- DEVICE Miltenyi device
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2015-05-06 |
| Est. Completion | 2027-05-01 |
| Phase | NA |
What NCT02438904 shows while recruiting
NCT02438904 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Blood And Marrow Transplantation appearing as the primary indexed condition, and to 2 interventions - of which CD34 Positive Stem Cell Infusion is the first listed.
NCT02438904 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02438904 about?
NCT02438904 is a clinical study titled "Compassionate Access of the Miltenyi Device for CD34+ Cell Selection". Objectives: Primary Objective To provide compassionate access to the Miltenyi device for CD34+ cell infusions to patients who experience poor graft function after stem cell transplantation (SCT).
What is the current status of trial NCT02438904?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2015-05-06. Estimated completion is 2027-05-01.
What conditions does trial NCT02438904 study?
This clinical trial studies the following conditions: Blood And Marrow Transplantation.
What interventions are being tested in trial NCT02438904?
The interventions under investigation include: CD34 Positive Stem Cell Infusion (BIOLOGICAL), Miltenyi device (DEVICE).
Who is sponsoring clinical trial NCT02438904?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02438904 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02438904's enrollment target sits among peer trials
200 506th of 2000 higher than 1,434 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI